All AbMole products are for research use only, cannot be used for human consumption.
CL2A-SN-38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an ADC. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make ADC. CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond.
NOTE: CL2A-SN-38 free base is less stable.
| Molecular Weight | 1480.61 |
| Formula | C73H97N11O22 |
| CAS Number | 1279680-68-0 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage | -20°C, dry, sealed, protect from light |
| Related Drug-Linker Conjugates for ADC Products |
|---|
| MC-SN38
MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). |
| DM4-SMCC
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker. |
| Lys-SMCC-DM1
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. |
| Doxorubicin-SMCC
Doxorubicin-SMCC is a agent-linker conjugate for ADC. |
| Mal-PEG4-VC-PAB-DMEA-PNU-159682
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
